Jianhua Chen

发表论文 115 篇 · 总被引 4081 次 · h-index 27

代表论文

• AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations (2022 · Journal of Clinical Oncology · 被引 247)
• Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (2022 · Journal of Clinical Oncology · 被引 210)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. (2022 · The Lancet Oncology · 被引 187)
• AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial (2023 · EClinicalMedicine · 被引 106)
• Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial. (2023 · Journal of Thoracic Oncology · 被引 66)
• On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial (2022 · Molecular Cancer · 被引 44)